Windtree Therapeutics, a Pennsylvania-based drug developer, is being delisted from Nasdaq due to its stock failing to meet the minimum bid price of $1 per share. This decision comes just over a month after the company announced a $700 million investment in Binance's BNB token, a move that did not improve its stock performance. Trading for Windtree's shares will be suspended as of August 21, following repeated violations of listing standards since at least June 2022. Despite a brief compliance in March 2025, the recent downturn in the cryptocurrency market heavily impacted Windtree's stock and its peers, prompting the company to shift to the over-the-counter market where regulations are less stringent. Analysts suggest that struggling firms entering the crypto treasury space may lack the operational substance seen in established companies, facing increasing skepticism in the market as they attempt to raise capital amid a downturn.

Source 🔗